Eagle Pharmaceuticals
50 Tice Blvd, Suite 315
Woodcliffe Lake
New Jersey
07677
United States
Tel: (201) 326-5300
Website: https://www.eagleus.com/
290 articles about Eagle Pharmaceuticals
-
Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017
10/31/2017
Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results.
-
Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute
10/30/2017
Eagle submitted, and the FDA accepted for filing, its NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for PEMFEXY ready-to-dilute in December 2016.
-
Eagle Pharmaceuticals Announces New Patent For RYANODEX
10/17/2017
Eagle Pharmaceuticals today announced that the Company has been issued a new patent related to its RYANODEX formulation (dantrolene sodium) by the United States Patent and Trademark Office (USPTO).
-
Eagle Pharma Licenses Japanese Rights For Bendamustine Hydrochloride Ready-To-Dilute And Rapid Infusion Injection Products To SymBio Pharma
9/20/2017
-
Eagle Pharma Announces Positive Results Of Study Conducted To Evaluate Neuroprotective Effects Of RYANODEX Secondary To Nerve Agent Exposure
9/5/2017
-
Eagle Pharma Reports Second Quarter 2017 Results
8/9/2017
-
Eagle Pharma To Discuss Second Quarter 2017 Financial Results On August 9, 2017
7/31/2017
-
Eagle Pharma Receives Complete Response Letter From FDA On RYANODEX For Exertional Heat Stroke Application
7/27/2017
-
Eagle Pharma Issues Statement Regarding RYANODEX Application PDUFA Date For Exertional Heat Stroke
7/25/2017
-
Eagle Pharma Appoints Pete A. Meyers As Chief Financial Officer
5/15/2017
-
Eagle Pharma Reports First Quarter 2017 Results
5/8/2017
-
Eagle Pharma To Discuss First Quarter 2017 Financial Results On May 8, 2017
4/25/2017
-
FDA Grants Priority Review For Eagle Pharma’ Ryanodex NDA For The Treatment Of Exertional Heat Stroke
3/27/2017
-
Eagle Pharma Announces Three New Patents Issued For Bendeka
3/21/2017
-
Eagle Pharma Appoints Richard A. Edlin To Board Of Directors
3/16/2017
-
Eagle Pharma Reports Fourth Quarter And Full Year 2016 Results
3/1/2017
-
Eagle Pharma’ Pemetrexed NDA Accepted For Filing By The FDA
2/28/2017
-
Eagle Pharma Announces 11th Patent Issued For Bendeka
2/28/2017
-
Eagle Pharma Announces New Patents Issued For Bendeka
2/21/2017
-
Eagle Pharma To Discuss Fourth Quarter And Full Year 2016 Financial Results On March 1, 2017
2/16/2017